Tanshinone IIA combined with cisplatin synergistically inhibits non‐small‐cell lung cancer in vitro and in vivo via down‐regulating the phosphatidylinositol 3‐kinase/Akt signalling pathway

Cisplatin represents one of the first‐line drugs used for non‐small‐cell lung cancer treatment. However, considerable side effects and the emergence of drug resistance are becoming critical limitations to its application. Combinatorial strategies may be able to extend the use of cisplatin. Both Tans...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Phytother Res
Main Authors: Liao, Xiao‐Zhong, Gao, Ying, Huang, Sheng, Chen, Zhuang‐Zhong, Sun, Ling‐Ling, Liu, Jia‐Hui, Chen, Han‐Rui, Yu, Ling, Zhang, Jia‐Xing, Lin, Li‐Zhu
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6772065/
https://ncbi.nlm.nih.gov/pubmed/31268205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ptr.6392
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados